Sign in to fuzzto save your conversations, follow your research and come back anytime.
Zim Laboratories
ZIMLAB
NSE
BSE
NSEBSESectorHealthcare
128.02
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Zim Laboratories shows strong innovation pipeline growth but faces sharp recent profitability and export revenue declines.
Innovative product contribution rose from 6.3% to 15% from Q1 FY26 to Q1 FY27 — stronger pipeline monetization
EBITDA margin fell from 13.4% to 3.7% from Q3 FY26 to Q1 FY27 — acute profitability stress
Innovative product revenue grew from ₹46 Cr to ₹138 Cr from Q1 FY26 to Q1 FY27 — higher sales from new launches
Profit after tax swung from ₹44 Cr to a loss of ₹40 Cr from Q3 FY26 to Q1 FY27 — severe bottom-line pressure
R&D allocation increased from ₹19 Cr to ₹82 Cr from Q2 FY26 to Q1 FY27 — sustained funding for future drugs
Finance cost rose from ₹29 Cr to ₹36 Cr from Q4 FY25 to Q1 FY27 — increasing debt servicing burden
Public shareholding expanded from 12% to 38.8% from Q4 FY25 to Q1 FY27 — broader retail investor base
Export revenue declined from ₹961 Cr to ₹792 Cr from Q3 FY26 to Q1 FY27 — cyclical overseas demand drop
